[Federal Register Volume 84, Number 161 (Tuesday, August 20, 2019)]
[Notices]
[Page 43148]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-17868]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Chris Kornak at 240-627-3705 or 
[email protected]. Licensing information may be obtained by 
communicating with the Technology Transfer and Intellectual Property 
Office, National Institute of Allergy and Infectious Diseases, 5601 
Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed 
Confidential Disclosure Agreement will be required to receive copies of 
unpublished information related to the invention.

SUPPLEMENTARY INFORMATION: Technology description follows:

Floxed Targeted Mouse Strain for Use in Conditional Deletion of the 
Irf8 Gene

Description of Technology

    IRF8, a member of interferon regulatory factor (IRF) family of 
transcription factors is a novel intrinsic transcriptional inhibitor of 
TH17-cell differentiation. TH17-cells are believed to be involved in 
the pathogenesis of various autoimmune/inflammatory diseases. The Irf8f 
floxed targeted mutated mouse strain can be used to selectively ablate 
expression of IRF8 in any cell type in which a Cre recombinase gene is 
activated. This will permit the identification of IRF8-regulated genes 
and their effects in specific types of developing and mature cells. 
These materials could be used to help define patterns of gene 
expression important for the development and function of cells 
including possible contributions to understanding: Normal immune 
responses, inflammatory conditions, autoimmunity and anti-viral 
responses.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404.

Potential Commercial Applications

     Target identification in B and T cell deficiency, 
macrophage defects and hematopoiesis.
     A tool for investigating IRF8 mediated issues associated 
with inflammation and autoimmunity.
     Investigative tool for development of potential 
therapeutics for lymphoma and Human Chronic Myeloid Leukemia.

Competitive Advantages

     Mice with established germ line transmission for use in 
conditional deletion of the IRF8 gene in any cell type.

Development Stage

     Research Use.
    Inventors: Herbert Carpenter Morse III (NIAID).
    Publications: Ouyang, Xinshou, et al. ``Transcription factor IRF8 
directs a silencing programme for TH17 cell differentiation.'' Nature 
Communications 2, Article number: 314 (2011).
    Licensing Contact: To license this technology, please contact Chris 
Kornak at 240-627-3705 or [email protected], and reference E-062-
2012-0.

    Dated: August 6, 2019.
Suzanne M. Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2019-17868 Filed 8-19-19; 8:45 am]
 BILLING CODE 4140-01-P